Oxford BioMedica PLC (OXBDF)

[marcusl2]

HTTP://www.fiercebiotech.com/biotech/adaptimmune-t-cell-therapy-snags-prime-status-putting-it-ema-s-nascent-fast-track

EMA’s Priority Medicines (PRIME) regulatory initiative. The scheme, which to date has accepted 8 drugs while rejecting almost 30, is designed to ensure developers of products with the potential to address major unmet needs receive support with regulatory applications and potentially accelerated reviews.EMA accepted requests for Novartis’ ($NVS) leukemia drug CTL019, Merck’s ($MRK) Ebola vaccine